🔥 #ESMO26 TLND omission after neoadjuvant IO in stage III #melanoma
🎙️ van Akkooi
Many centres already omit TLND with local, non evidence-based strategies outside PRADO.
Two trials will give the answer:
➡️ OMIT (NL): nivo+ipi, ILN MPR → omit TLND
➡️ MSLT-3: randomised ILN-only vs TLND, response-adapted, n≈1,574
@_SEOM @myESMO @oncodaily
#IO
63 views · 2 likes · 0 reposts · 0 replies
STARBOARD phase 3: A randomized, double-blind study of first-line (1L) encorafenib (enco), binimetinib (bini), and pembrolizumab (pembro) vs placebo (pbo) and pembro for unresectable locally advanced or metastatic BRAF V600-mutant melanoma
https://esmocongress.esmo.orgEfficacy and safety of lifileucel and pembrolizumab in patients with immune check point inhibitor-naïve advanced melanoma: Final results from IOV-COM-202 study
https://esmocongress.esmo.orgTranscriptomic and epigenomic profiling of TIL products identifies determinants of clinical benefit in advanced melanoma
https://esmocongress.esmo.orgEmotional distress (ED) upfront neoadjuvant ipilimumab + nivolumab (IPI+NIVO) is associated with lower pathological response and toxicity
https://esmocongress.esmo.orgImpact of BRAF V600K mutation in patients with resectable stage III melanoma: A subgroup analysis of the NADINA trial
https://esmocongress.esmo.orgINTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgSource: Yago Garitaonaindía · x.com